How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Is the proposed process for updating and withdrawing the TAs appropriate to achieve useful and usable guidance?

  • Question on Consultation

    Is the proposed process sufficiently clear? Are further details of the proposed process required by stakeholders?

  • Question on Consultation

    Should NICE consider adapting other elements of the proposed process to achieve more useful and usable guidance?

  • Question on Consultation

    Do you have any other comments on the proposed process for updating the TAs within the proportionate decision-making process?

  • Question on Consultation

    Would it be challenging to implement of any of the recommendations for the updated TAs? Please say why and for whom, and how these could be mitigated.

  • Question on Consultation

    Would implementation of any of the recommendations have significant cost implications?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Review proposal of TA388, TA679, TA773

Closed for comments This consultation ended on at   Request commenting lead permission

Summary of TAs to be considered for review

A summary of the TAs to be considered for review is listed in Table 1.

Table 1: TAs to be considered for review

TA number

Title

Recommendation

Year of publication

TA388

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction

Sacubitril valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction, only in people:

  • with New York Heart Association (NYHA) class 2 to 4 symptoms and

  • with a left ventricular ejection fraction of 35% or less and

  • who are already taking a stable dose of angiotensin‑converting enzyme (ACE) inhibitors or angiotensin II receptor‑blockers (ARBs).

2016

TA679

Dapagliflozin for treating chronic heart failure with reduced ejection fraction

Dapagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:

  • angiotensin-converting enzyme (ACE) inhibitors or angiotensin‑2 receptor blockers (ARBs), with beta blockers, and, if tolerated, mineralocorticoid receptor antagonists (MRAs), or

  • sacubitril valsartan, with beta blockers, and, if tolerated, MRAs.

2021

TA773

Empagliflozin for treating chronic heart failure with reduced ejection fraction

Empagliflozin is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction in adults, only if it is used as an add-on to optimised standard care with:

  • an angiotensin-converting enzyme (ACE) inhibitor or angiotensin 2 receptor blocker (ARB), with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA), or

  • sacubitril valsartan with a beta blocker and, if tolerated, an MRA.

2022